Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

Juniper Pharmaceuticals, Inc., today announced financial results for the three-month period ended March 31, 2015.

6 May 2015

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

Indivior PLC today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period.

5 May 2015

UNC researchers use exosomes to deliver potent Parkinson's treatment directly to the brain

Researchers at the University of North Carolina at Chapel Hill have used exosomes -- tiny bubbles of protein and fat produced naturally by cells -- to bypass the body's defenses and deliver a potent antioxidant directly to the brain to treat Parkinson's disease.

5 May 2015

Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the State Intellectual Property Office of China granted a process patent for its novel stem-cell based drug Stempeucel.

28 Apr 2015

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi Pharmaceuticals, Inc. today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths.

27 Apr 2015

New fluid gels delay release of drugs to benefit young children, others

SCIENTISTS at the University of Huddersfield are pioneering the use of a special gel that is ideal for administering medication to young children and others - including the elderly - who have difficulty swallowing pills and capsules. Unlike purely liquid medicines, the gel delays the release of the drug, so that it has maximum effect.

27 Apr 2015

New Cannabis and Cannabinoid Research journal to be launched in fall 2015

Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.

25 Apr 2015

Copley Scientific to showcase new accessories at RDD Europe 2015

Cascade impaction is used for all inhaled product testing but is a manually intensive process. Copley Scientific’s sample preparation tools help to alleviate bottlenecks, ensure that testing is consistent, reproducible and controlled, and also reduce the risk of repetitive strain injury (RSI)...

24 Apr 2015

Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced additional details of its new Phase 2 clinical trial (the 2015 WF10 Trial) to assess WF10 for the treatment of allergic rhinitis.

22 Apr 2015

Electronic cigarettes pose particular risks to the developing brains, organs of young people

Although heavily promoted as a safer cigarette and an aid to quit smoking, electronic cigarettes and the nicotine they deliver pose particular risks to the developing brains and organs of children. Use of electronic cigarettes by school-age children has surpassed traditional cigarette smoking, and it is critical to recognize and understand the risks related to nicotine exposure, addiction, and the poor regulation of these products, as described in the comprehensive Review article "Electronic Cigarettes: Vulnerability of Youth," published in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

22 Apr 2015

Novel treatment strategy targets treatment-resistant CML

Researchers have shown that the coiled-coil mimetic CCmut3 can inhibit cell growth and promote apoptosis in cell lines expressing BCR–ABL1, including those resistant to tyrosine kinase inhibitors.

20 Apr 2015

New set of molecules could carry medicines into cells

Just as a scientist dressed in a lab coat and goggles might get stuck behind the velvet rope at a trendy bar, many otherwise good drugs can't get inside cells if they don't look the part. In a report published this week in ACS Central Science, researchers report a new set of molecules that could ferry medicines into cells by taking on the right charge and shape, easily sliding past lipid membranes.

16 Apr 2015

Intelligent Hospital Association recognizes Ochsner with Best Comprehensive Integration award

The Intelligent Hospital Association today announced that Ochsner Health System was awarded the Best Comprehensive Integration for 2014. The award is given to a hospital or health system that effectively and seamlessly integrates technologies to provide a comprehensive solution in a health care facility.

15 Apr 2015

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate™ system to a medical center located in Hungary.

14 Apr 2015

CareFusion showcases new medication management technologies at HIMSS annual conference

CareFusion, a BD company, today announced it is demonstrating several new medication management technologies at the Healthcare Information Management and Systems Society annual conference in the Intelligent Health Pavilion and Interoperability Showcase.

14 Apr 2015

Particle Sciences receives patent for its surface arrayed therapeutics drug delivery platform

Particle Sciences, a leading drug delivery CDMO, has received a Notice of Allowance for composition and use of the technology incorporated into its SATx™ platform...

9 Apr 2015

Prolong Pharmaceuticals' SANGUINATE granted FDA Orphan Drug Designation for SCD treatment

Prolong Pharmaceuticals, LLC, a biopharmaceutical company dedicated to developing products for the treatment of anemias, cancers and their debilitating comorbidities, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its flagship product SANGUINATE for the treatment of Sickle Cell Disease (SCD).

8 Apr 2015

Watching the blood flow

Optical microangiography (OMAG), a technique based on optical coherence tomography, can be used to visualize the microvasculature network under inflamed skin condition. It opens up new vistas for clinical trials of treatment and diagnosis of inflammatory skin disorders.

7 Apr 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.

6 Apr 2015

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Columbia Laboratories, Inc., today announced that it will adopt Juniper Pharmaceuticals, Inc. as its new corporate brand. The name change will become effective Friday, April 10, 2015, and the Company's common stock will begin trading on the Nasdaq Stock Exchange under the new ticker symbol — "JNP" — on Monday, April 13, 2015.

2 Apr 2015

Drug Delivery News and Research

Further Reading

Juniper's total revenues increase 19% to $8.3 million in first quarter 2015

Indivior reports top-line results from RBP-7000 phase 3 trial for treatment of schizophrenia

UNC researchers use exosomes to deliver potent Parkinson's treatment directly to the brain

Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

New fluid gels delay release of drugs to benefit young children, others

New Cannabis and Cannabinoid Research journal to be launched in fall 2015

Copley Scientific to showcase new accessories at RDD Europe 2015

Nuvo Research provides details of new WF10 Phase 2 clinical trial for treatment of allergic rhinitis

Electronic cigarettes pose particular risks to the developing brains, organs of young people

Novel treatment strategy targets treatment-resistant CML

New set of molecules could carry medicines into cells

Intelligent Hospital Association recognizes Ochsner with Best Comprehensive Integration award

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

CareFusion showcases new medication management technologies at HIMSS annual conference

Particle Sciences receives patent for its surface arrayed therapeutics drug delivery platform

Prolong Pharmaceuticals' SANGUINATE granted FDA Orphan Drug Designation for SCD treatment

Watching the blood flow

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Columbia Laboratories to adopt Juniper Pharmaceuticals brand marks

Must Know Trends for Drug Delivery Systems and the Crucial Role of Materials Testing eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo